Stockscreener 앱 받기
9.62
8.56%
-0.90
시간 외 거래:
9.74
0.12
+1.25%
전일 마감가:
$10.52
열려 있는:
$10.4
하루 거래량:
31,033
Relative Volume:
0.65
시가총액:
$34.25M
수익:
-
순이익/손실:
$-55.84M
주가수익비율:
-0.5467
EPS:
-17.5951
순현금흐름:
$-49.61M
1주 성능:
-17.78%
1개월 성능:
-3.90%
6개월 성능:
+3.77%
1년 성능:
+1,991%
1일 변동 폭
$9.60
$11.02
1주일 범위
$9.60
$13.18
52주 변동 폭
$0.3412
$15.74
Nextcure Inc Stock (NXTC) Company Profile
명칭
Nextcure Inc
전화
240-399-4900
주소
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
9.62 | 37.46M | 0 | -55.84M | -49.61M | -17.60 |
VRTX
Vertex Pharmaceuticals Inc
|
426.01 | 109.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
744.44 | 79.46B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
783.74 | 48.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
308.51 | 40.77B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.90 | 33.39B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-07 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2022-11-04 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2022-03-01 | 개시 | Ladenburg Thalmann | Buy |
| 2021-03-05 | 업그레이드 | Truist | Hold → Buy |
| 2021-01-15 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-07-16 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-07-13 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-07-13 | 다운그레이드 | SunTrust | Buy → Hold |
| 2020-06-01 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-05-26 | 개시 | JMP Securities | Mkt Outperform |
| 2020-03-24 | 개시 | The Benchmark Company | Buy |
| 2020-03-02 | 개시 | ROTH Capital | Buy |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-12-05 | 개시 | Needham | Buy |
| 2019-11-26 | 개시 | BTIG Research | Buy |
| 2019-07-09 | 개시 | BofA/Merrill | Buy |
| 2019-06-03 | 개시 | Morgan Stanley | Overweight |
| 2019-06-03 | 개시 | Piper Jaffray | Overweight |
모두보기
Nextcure Inc 주식(NXTC)의 최신 뉴스
NextCure (NASDAQ: NXTC) plans 2026 meeting, auditor, pay and equity plan votes - Stock Titan
NextCure to present SIM0505 cancer drug data at ASCO meeting - Investing.com
NextCure to present SIM0505 cancer drug data at ASCO meeting By Investing.com - Investing.com Canada
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026 - The Manila Times
NextCure and Simcere Announce Presentation of Phase 1 Data for SIM0505 at ASCO 2026 - Quiver Quantitative
NextCure Inc stock (US65343E1082): Is its immunotherapy pipeline strong enough to unlock biotech ups - AD HOC NEWS
Ladenburg Thalmann Upgrades NextCure (NXTC) - MSN
NXTC Forecast, Price Target & Analyst Ratings | NEXTCURE INC (NASDAQ:NXTC) - ChartMill
Resistance Check: Will Argan Inc benefit from rate cutsPortfolio Update Report & Risk Managed Trade Strategies - baoquankhu1.vn
GUOCHUN INTERNATIONAL INC. Reports No Revenue and Material Weaknesses in Q3 2025 10-Q/A Filing - Minichart
Published on: 2026-04-09 04:19:51 - baoquankhu1.vn
Surprises Report: Is NextCure Inc stock good for income investorsNew Guidance & Safe Entry Trade Signal Reports - baoquankhu1.vn
FDA Gives Fast Track Status to SIM0505 in Platinum-Resistant Ovarian Cancer - CancerNetwork
Activity Recap: Is NextCure Inc a defensive stock2026 News Drivers & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Is NextCure (NXTC) Stock heavily shorted | Price at $12.10, Up 8.67%Vega Volatility - Cổng thông tin điện tử Tỉnh Sơn La
Value Recap: How is NextCure Inc managing supply chain issues2026 Geopolitical Influence & Verified Short-Term Plans - baoquankhu1.vn
NextCure Gets FDA Fast Track for SIM0505 in Ovarian Cancer - National Today
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer - Bitget
FDA fast-tracks NextCure ovarian cancer drug ahead of ASCO data - Stock Titan
Resistance Check: Is NextCure Inc exposed to currency risksMarket Performance Recap & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Trend Report: Will Investcorp Credit Management BDC Inc Preferred Security outperform tech stocksWeekly Investment Summary & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
NXTC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
Sacral Fracture Risk After Short-Course RT for Rectal Cancer - Medscape
NXTC Stock Analysis: NextCure Inc. Biotech Gains 1.80 Percent to 10.72 Support Level - Xã Thanh Hà
Buyout Rumor: Will American Tower Corporation stock go up in YEAR2026 Key Lessons & Stepwise Trade Signal Guides - baoquankhu1.vn
NXTC Should I Buy - Intellectia AI
NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026 - The Manila Times
Phase 1 cancer drug abstract lands ASCO 2026 slot in Chicago - Stock Titan
Price Action: Is Oriental Culture Holding LTD stock a top performer YTD2026 Selloffs & Daily Entry Point Trade Alerts - baoquankhu1.vn
Stock List: Research Stocks from Around the World - GuruFocus
BLRX PE Ratio & Valuation, Is BLRX Overvalued - Intellectia AI
Bond Watch: Is NextCure Inc stock showing strong momentumQuarterly Portfolio Summary & Verified Entry Point Signals - baoquankhu1.vn
NextCure, Inc.Common Stock (NQ: NXTC - FinancialContent
Retail Trends: Why is GGNPRB stock going downLong Setup & Smart Investment Allocation Insights - baoquankhu1.vn
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
NIVFPrice, Charts & Blockchain Insights - Intellectia AI
ITVI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
MMMM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Buy Signal: Is NextCure Inc a defensive stockQuarterly Trade Review & Growth-Oriented Investment Plans - baoquankhu1.vn
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Aug Action: Is CF Bankshares Incs growth already priced in2026 Chart Watch & Proven Capital Preservation Methods - baoquankhu1.vn
Published on: 2026-03-22 18:56:49 - baoquankhu1.vn
BOLD Technical Analysis & Price Forecast - Intellectia AI
LOW Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
HTH Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
BKT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
BSX Technical Analysis & Price Forecast - Intellectia AI
CULP Should I Buy - Intellectia AI
Travel Stocks: Is NextCure Inc stock good for income investorsTrade Risk Assessment & AI Forecast Swing Trade Picks - baoquankhu1.vn
NextCure Inc Stock (ISIN: US65343E1082) Faces Analyst Downgrade Amid Biotech Sector Headwinds - AD HOC NEWS
Nextcure Inc (NXTC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.61%
3.22%
자본화:
|
볼륨(24시간):